Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel in Node-Positive Breast Cancer
NCT00004125Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 1999
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and docetaxel in breast cancer (4 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Disease-Free Survival and Overall Survival. Started Nov 1999; status: completed.
02
Drugs
paclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004125.